公开(公告)号：US10457747B2

公开(公告)日：2019-10-29

申请号：US15549087

申请日：2016-03-11

申请人： BIOTECH PHARMACEUTICAL CO. LTD ,  CENTRO DE INMUNOLOGIA MOLECULAR

发明人： MeyLen Chea ,  Julio Palacios ,  Miguel Arias ,  Loany Calvo ,  Tamara González ,  Rolando Pérez ,  Zhi Bai ,  Yuemao Liu ,  Kaiheng Xiao ,  Xiao Chen ,  Zhenhua He ,  Yangliu Cai ,  Zhenhua Yang ,  Xianhong Bai

IPC分类号： C07K16/44 ,  C12P21/02 ,  A61K39/00

摘要： Provided is a method for obtaining high-yield, stable expression cell clones from myeloma cell lines in a protein-free culture medium. The method is used for industrial production of a recombinant antibody, and includes three stage: (1) adapting to a protein-free culture medium, statically culturing cells at a low density, and gradually reducing a fat-rich supplement to a chemical culture medium; (2) adapting to a protein-free culture medium; culturing cells at a high density, and using a perfusion fermentation system in a laboratory scale; and (3) screening high-yield, stable expression cell clones from the cells after fermentation ends. The cell clone may be used to produce a humanized anti-NeuGcGM3 14F7 recombinant antibody.

公开(公告)号：US20180016353A1

公开(公告)日：2018-01-18

申请号：US15549087

申请日：2016-03-11

申请人： BIOTECH PHARMACEUTICAL CO. LTD ,  CENTRO DE INMUNOLOGIA MOLECULAR

发明人： MeyLen CHEA ,  Julio PALACIOS ,  Miguel ARIAS ,  Loany CALVO ,  Tamara GONZÁLEZ ,  Rolando PÉREZ ,  Zhi BAI ,  Yuemao LIU ,  Kaiheng XIAO ,  Xiao CHEN ,  Zhenhua HE ,  Yangliu CAI ,  Zhenhua YANG ,  Xianhong BAI

IPC分类号： C07K16/44 ,  C12P21/02 ,  A61K39/00

摘要： Provided is a method for obtaining high-yield, stable expression cell clones from myeloma cell lines in a protein-free culture medium. The method is used for industrial production of a recombinant antibody, and includes three stage: (1) adapting to a protein-free culture medium, statically culturing cells at a low density, and gradually reducing a fat-rich supplement to a chemical culture medium; (2) adapting to a protein-free culture medium; culturing cells at a high density, and using a perfusion fermentation system in a laboratory scale; and (3) screening high-yield, stable expression cell clones from the cells after fermentation ends. The cell clone may be used to produce a humanized anti-NeuGcGM3 14F7 recombinant antibody.